Clinical trials: Tumor Immunity
Central Nervous System Neoplasm
High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors
This pilot clinical trial studies high-dose trivalent influenza vaccine in inducing immune response patients with central nervous system tumors.
- Trial name
- NCT01941758
- Testing
- trivalent influenza vaccine, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Solid Cancer
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours.
- Trial name
- NCT06697665
- Testing
- LM103
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Human Papillomavirus Infection
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human papillomavirus (HPV) is a member of the Papillomaviridae family of DNA viruses that is capable of infecting humans. HPV infection can cause cancers of the cervix, vulva, vagina, and anus in women or cancers of the anus and…
- Trial name
- TRAP-HPV (NCT01824537)
- Testing
- HPV vaccine, Gardasil 9, Hepatitis A vaccine
- Where
- Canada
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- McGill University
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
Multiple Myeloma (MM), CAR T Cells
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of…
- Conditions
- Multiple Myeloma (MM), CAR T Cells, Bispecific Antibodies
- Trial name
- BEAM-MM (NCT07564219)
- Testing
- Ketogenic diet, Ketogenic Drinks
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Advanced Lung Carcinoma, Metastatic Lung Carcinoma
A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer
This phase IIb trial studies the effect of a biobehavioral/cognitive (ABC) treatment on stress, depression, and anxiety in patients with stage IV lung cancer.
- Conditions
- Advanced Lung Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05342571
- Testing
- Behavioral, Psychological or Informational Intervention, Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Epstein Barr Virus (EBV) Infection
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
To evaluate the safety, immune-response and efficacy of GSK Biologicals' EBV vaccine in a population at risk of developing infectious mononucleosis.
- Trial name
- NCT00430534
- Testing
- EBV vaccine (268664)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Henogen
Melanoma
Study of Anti-telomerase T CD4 Immunity in Melanoma
The impressive clinical responses obtained with immune checkpoint inhibitors (anti-PD-1/PDL-1, anti-CTLA-4) indicate that the presence of preexisting antitumor immune response might be required for their efficacy and highlight…
- Trial name
- LyTéloMel (NCT02838433)
- Testing
- biological samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
B-cell Malignancies
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).
- Trial name
- NCT03701438
- Testing
- Influenza Vaccine
- Where
- 2 sites in Czechia, Spain
- Volunteers
- 2 people
- Sponsor
- Gilead Sciences
Cancer
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
- Trial name
- I-SPARC (NCT05075538)
- Testing
- Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1
- Where
- 2 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- Jules Bordet Institute
High Grade Glioma
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
- Trial name
- NCT02041611
- Testing
- Blood collections
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer, Glioma
Study of the Anti-tumoral Immune Response
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
- Trial name
- ERISA (NCT02854644)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 167 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Cell Carcinoma
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked…
- Trial name
- NCT01147536
- Testing
- HSPPC-96
- Where
- 3 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Agenus Inc.
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival…
- Trial name
- NADIM-ADJUVANT (NCT04564157)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- 30 sites in Spain
- Volunteers
- 210 people
- Sponsor
- Fundación GECP
Cancer
Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center
Special populations are people with a risk to dévelop severe forms of a disease. The immunogenicity and efficacy of vaccines in this population may be different compared of the general population.
- Trial name
- CANSEROVAX (NCT04935528)
- Testing
- serology and ELISPOT test, serology
- Where
- France
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Diseases, Chronic, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the…
- Conditions
- Diseases, Chronic, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIM-PBD (NCT05043246)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies B
Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B
Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells.
- Trial name
- Epitopes-LNH01 (NCT02844491)
- Testing
- additional biological samples
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon